Description
Details
PureStem® EN7 Progenitor expresses neurofilament, medium polypeptide (NEFM), RGS1, tyrosine hydroxylase (TH), sarcosin (KBTBD10), gamma-aminobutyric acid (GABA) A receptor, beta 1 (GABRB1) (useful in screening for psychoactive drugs including those for the treatment of schizophrenia), the tight junction protein CLDN5, and MASP1. The most distal HOX gene expression is HOXA2, B2. Upon differentiation (14 day in 100 ng/ml EGF) PureStem Progenitor EN7 up-regulates the osteogenic factor COMP and PTGDS (prostaglandin D2 synthase (brain)). PureStem Progenitor EN7 was derived from the parental hES cell line WA09 as described (West, M.D. et al, 2008).
Propagation Potential
PureStem Progenitor EN7, is sold at passage 12 (the original clonal isolate confluent in a 1.9 cm2well was P1), which corresponds to approximately 15 doublings since the first 1.9 cm2 well and approximately 33 doublings since its original clonal plating.
Propagation Potential
PureStem Progenitor EN7, is sold at passage 12 (the original clonal isolate confluent in a 1.9 cm2well was P1), which corresponds to approximately 15 doublings since the first 1.9 cm2 well and approximately 33 doublings since its original clonal plating.
Details
Details
Quality Control | This line is negative for HIV (1, 2), HBV, HCV, bacteria, mycoplasma, and fungal contamination. Certificates of analysis are available on request. |
---|---|
Technical Documents | ES-184 Technical Data Sheet |
References | West MD, et al. (2008) The ACTCellerate initiative: large-scale combinatorial cloning of novel human embryonic stem cell derivatives. Regen Med. 3(3):287-308. PMID: 18462054 |